Sign In
Buy PRLD
$3.66
+0.160 (+4.57%)
At Close: Jun 03, 2026
Prelude Therapeutics Incorporated (PRLD) Q3 2025 Earnings Call Transcript
08:31pm, Wednesday, 12'th Nov 2025
Prelude Therapeutics Incorporated ( PRLD ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Bryant Lim - CFO, Chief Legal Officer & Corporate Secretary Krishna Vaddi - Founder,
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:01am, Wednesday, 12'th Nov 2025
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
11:24pm, Tuesday, 11'th Nov 2025
LOS ANGELES--(BUSINESS WIRE)---- $PRLD--PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm.
Prelude Therapeutics Announces Strategic Business Update
07:05am, Tuesday, 04'th Nov 2025
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
07:01am, Tuesday, 04'th Nov 2025
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients
Prelude Therapeutics (PRLD) Projected to Post Earnings on Wednesday
02:45am, Tuesday, 04'th Nov 2025
Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) will likely be releasing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings
WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
07:30am, Friday, 17'th Oct 2025
WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to i
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Thursday, 14'th Aug 2025
PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial c
Two Sigma Investments LP Purchases 174,906 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD)
03:34am, Wednesday, 11'th Jun 2025
Two Sigma Investments LP grew its position in Prelude Therapeutics Incorporated (NASDAQ:PRLD – Free Report) by 307.2% in the fourth quarter, according to its most recent 13F filing with the Secu
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
07:30am, Monday, 02'nd Jun 2025
WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will parti
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 06'th May 2025
PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prel
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
07:30am, Thursday, 01'st May 2025
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will partic
Prelude Announces Presentations at 2025 AACR Annual Meeting
04:05pm, Friday, 25'th Apr 2025
Preclinical data elucidating the mechanism of action of PRT3789, Prelude's first-in-class, highly selective SMARCA2 degrader currently in early clinical development
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know
01:01pm, Thursday, 10'th Apr 2025
Prelude Therapeutics (PRLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
